From Research at med.fsu.edu Thu Mar 5 10:55:15 2020 From: Research at med.fsu.edu (Med Research) Date: Thu, 5 Mar 2020 15:55:15 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE01E6DDE73D@FSUCOM128.med.ad.fsu.edu> Donaghue Foundation: Research to Improve Health of Older Adults in Long-Term Care Facilities The Donaghue Foundation welcomes applications to its Another Look 2020 grant program. The program supports health-related research projects with the potential to improve the quality of care and life for adults age 65 or older who are long-term residents living in nursing homes, assisted living facilities, and other congregate care facilities. The foundation welcomes all topics related to improving quality in long-term care facilities but is particularly interested in supporting the following topics: increasing the availability and use of palliative, end of life, and hospice care; assessing the impact of innovations in staffing roles and expertise on resident quality of life; assessing the role of family members and informal caregivers on resident quality of life; understanding and reducing the impact of ageism on resident health and well-being; reducing isolation and loneliness and their negative impact on resident health and well-being; addressing racial, ethnic, gender or income disparities in care quality or health outcomes; and enhancing understanding of the specialized care needs of resident populations with developmental disabilities or with serious mental illness. In 2020, the foundation will invest a total of approximately $750,000 in the program and expects to make four or five awards. Projects may be up to two years in length. Letter of intent due March 25, 2020. Med-RA deadline to receive draft documents: March 12. Fahs-Beck Fund for Research and Experimentation: Faculty/Post-Doctoral Grant Program (Fahs-Beck Fellows) Grants of up to $20,000 are available to help support the research of faculty members or post-doctoral researchers affiliated with non-profit human service organizations in the United States and Canada. Areas of interest to the Fund are: studies to develop, refine, evaluate, or disseminate innovative interventions designed to prevent or ameliorate major social, psychological, behavioral or public health problems affecting children, adults, couples, families, or communities, or studies that have the potential for adding significantly to knowledge about such problems. The research for which funding is requested must focus on the United States or Canada or on a comparison between the United States or Canada and one or more other countries. Due April 1, 2020 and November 1, 2020. Med-RA deadline to receive draft documents for April 1, 2020 deadline: March 19. ADDF-Harrington Scholar Program The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer?s disease and related dementias. This unique award provides funding and committed project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer?s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. Average award: Up to $600,000 over 2 years with dedicated support from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology and toxicology, and business development. The expertise of each team is tailored to the specific needs of the project during the two-year award period. Letter of intent due April 20, 2020. Application due July 31, 2020. Med-RA deadline to receive draft documents for April 20, 2020 letter of intent deadline: April 7. Simons Foundation Autism Research Initiative (SFARI): Collaboration on Sex Differences in Autism SFARI Collaborations are a new funding mechanism that will provide substantive and stable funding support to multidisciplinary teams of investigators tackling critical issues in the autism research field. Collaborations will be led by a director who oversees interdisciplinary, synergistic research efforts across multiple laboratories. Investigative groups within a Collaboration will focus on the same conceptually unified topic but will incorporate different scientific disciplines, multiple levels of analysis, and will include a robust data-sharing infrastructure. SFARI Collaborations have a maximum budget of up to $8,000,000, including 20 percent indirect costs, over an initial period of four years, with a possible three-year extension. Letter of intent due April 21, 2020. Med-RA deadline to receive draft documents: April 8. Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required) This milestone-driven Funding Opportunity Announcement (FOA) invites applications for single-site, biphasic, late-stage implementation and translation (T4) research trials to identify and test pragmatic and sustainable implementation strategies that will increase the use of evidence-based practices (EBP), i.e., evidence-based guidelines or other well-accepted evidence-based interventions, for preventing and/or managing heart, lung, and blood diseases and/or sleep (HLBS) disorders. Applicants will be expected to address a planning phase (R61) of up to one year, and an implementation research phase (R33) of up to four years for the clinical trial. During the planning phase awardees will be expected to: finalize selection of the EBP; recruit participating organization(s); prepare the implementation protocol; develop milestones and a project timeline; and develop plans for data collection and management, and participant recruitment and retention. Robust plans for the implementation research clinical trial and the supporting implementation strategy dissemination package are required for the R33 phase of the application. Upon administrative review by the NHLBI, only meritorious R61 projects that meet the predetermined scientific milestones will be selected to transition to the R33 phase. Investigators with expertise in T4 clinical trials and hybrid studies for heart, lung, blood, or sleep conditions are expected to be part of the research team. In addition, applications proposing collaborative investigative teams combining expertise in qualitative methods, administration of T4 implementation clinical trials as appropriate at various levels (e.g., individual, clinical practice, facility, etc.), quality improvement, health economics, implementation of skills development programs, and robust experience in the adaptation and implementation of other established EBP will be encouraged. Personnel involved in the proposed strategy, e.g., nurse practitioners, patient, family members, respiratory therapists, pharmacists, hospital intensivists, etc., should be meaningfully engaged in the conceptualization and the planned execution of the proposed project. Applications proposing to establish a new EBP are not within the scope of this FOA. Due May 1, 2020. Med-RA deadline to receive draft documents: April 20. Surgical Disparities Research (R01 ? Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. While the goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, this initiative will also seek to identify multi-level strategies at the institutional and systems level. Due May 5, 2020. Med-RA deadline to receive draft documents: April 22. Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI). Due May 11, 2020 and May 11, 2021. Med-RA deadline to receive draft documents for May 11, 2020 deadline: April 28. Leadership Award for Alzheimer?s Disease and Related Dementias Research (R35 Clinical Trial Not Allowed) Applicants will be supported to develop and implement innovative multidisciplinary research and mentoring programs through an interchange of ideas that enable individuals and their institutions to strengthen existing programs and the development of new research programs that are specific to the goals/milestones of the NIH Alzheimer's Disease and Alzheimer's Disease Related Dementias Summits. Due June 19, 2020. Med-RA deadline to receive draft documents: May 27. NIAMS Clinical Trial Planning Grant (R34) ? Clinical Trial Not Allowed This Funding Opportunity Announcement (FOA) will support planning grants for investigator-initiated clinical interventional trials. The R34 planning grant is designed to enable the necessary planning, design, and preparation of documentation prior to implementation of investigator-initiated clinical trials. Completion of the agreed upon milestones of an R34 planning grant or documentation that planning has been addressed is required prior to submission of an application through a NIAMS U01 clinical trial implementation application that will support the actual implementation and conduct of the study. The planning should facilitate the launching of a trial that is hypothesis-driven, milestone-defined, and has the potential for high impact within the research mission of the NIAMS. Due July 1, 2020; November 2, 2020; March 1, 2021; July 1, 2021; November 1, 2021; March 1, 2022; July 1, 2022; and November 1, 2022. ed-RA deadline to receive draft documents for July 1, 2020 deadline: June 18. NSF: Perception, Action & Cognition The PAC program funds theoretically motivated research on a wide-range of topic areas related to typical human behavior with particular focus on perceptual, motor, and cognitive processes and their interactions. Central research topics for consideration by the program include (but are not limited to) vision, audition, haptics, attention, memory, written and spoken language, spatial cognition, motor control, categorization, reasoning, and concept formation. Of particular interest are emerging areas, such as the interaction of sleep or emotion with cognitive or perceptual processes, epigenetics of cognition, computational models of cognition, and cross-modal and multimodal processing. The program welcomes a wide range of perspectives, such as individual differences, symbolic and neural-inspired computation, ecological approaches, genetics and epigenetics, nonlinear dynamics and complex systems, and a variety of methodologies spanning the range of experimentation and modeling. The PAC program is open to co-review of proposals submitted to other programs both within the Social, Behavioral, and Economic Sciences Directorate and across other directorates. Note: Proposals may be returned without review if the major focus is 1) the organization of neural activity or brain networks; 2) understanding clinical populations; or 3) non-human animals without a clear and direct impact on our understanding of human perception, action, or cognition. Investigators are encouraged to send the program director a one-page summary of the proposed research before submitting a proposal, in order to determine its appropriateness for the PAC program. Due August 3, 2020. Med-RA deadline to receive draft documents: July 21. NSF: Science of Organizations Organizations -- private and public, established and entrepreneurial, designed and emergent, formal and informal, profit and nonprofit -- are critical to the well-being of nations and their citizens. They are of crucial importance for producing goods and services, creating value, providing jobs, and achieving social goals. The Science of Organizations (SoO) program funds basic research that yields a scientific evidence base for improving the design and emergence, development and deployment, and management and ultimate effectiveness of organizations of all kinds. SoO funds research that advances our fundamental understanding of how organizations develop, form and operate. Successful SoO research proposals use scientific methods to develop and refine theories, to empirically test theories and frameworks, and to develop new measures and methods. Funded research is aimed at yielding generalizable insights that are of value to the business practitioner, policy-maker and research communities. SoO welcomes any and all rigorous, scientific approaches that illuminate aspects of organizations as systems of coordination, management and governance. In considering whether a particular project might be a candidate for consideration by SoO, please note: * Intellectual perspectives may involve (but are not limited to) organizational theory, behavior, sociology or economics, business policy and strategy, communication sciences, entrepreneurship, human resource management, information sciences, managerial and organizational cognition, operations management, public administration, social or industrial psychology, and technology and innovation management. * Phenomena studied may include (but are not limited to) structures, routines, effectiveness, competitiveness, innovation, dynamics, change and evolution. * Levels of analysis may include (but are not limited to) organizational, cross-organizational collaborations or relationships, and institutional and can address individuals, groups or teams. * Research methods may be qualitative and quantitative and may include (but are not limited to) archival analyses, surveys, simulation studies, experiments, comparative case studies, and network analyses. Projects that aim to implement and subsequently evaluate particular organizational training, effectiveness or change programs, rather than to advance fundamental, generalizable knowledge, are not appropriate for SoO. Due September 3, 2020. Med-RA deadline to receive draft documents: August 24. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon Mar 9 11:05:34 2020 From: Research at med.fsu.edu (Med Research) Date: Mon, 9 Mar 2020 15:05:34 +0000 Subject: Weekly funding Opportunities and NIH Grant Writing Workshop Message-ID: <60E19361B71BE04F835C1FB3C18361BE01E6DDE8A0@FSUCOM128.med.ad.fsu.edu> NIH Grant Writing Workshop ? SAVE THE DATE The FSU Office of Research Development (ORD) is partnering with FAMU to offer a free two day intensive NIH grant writing workshop. The workshop will be held April 20-21, 2020. The location and registration site are still in development, but ORD will provide more information soon. Congressionally Directed Medical Research Programs Autism Research Program Clinical Trial Award Pre-application: April 15, 2020. Invited full application: July 16, 2020. Idea Development Award Pre-application: April 15, 2020. Invited full application: July 16, 2020. Clinical Translational Research Award Pre-application: April 15, 2020. Invited full application: July 16, 2020. Med-RA deadline to receive draft documents for April 15, 2020 pre-applications: April 1. Ovarian Cancer Research Program Clinical Translational Research Award Pre-application: April 23, 2020. Application: July 30, 2020. Investigator-Initiated Research Award Pre-application: April 23, 2020. Application: July 30, 2020. Ovarian Cancer Academy Award - Early Career Investigator Pre-application: April 23, 2020. Application: July 30, 2020. Pilot Award Pre-application: April 23, 2020. Application: July 30, 2020. Med-RA deadline to receive draft documents for April 23, 2020 pre-applications: April 14. Peer Reviewed Medical Research Program Topic Areas: Arthritis, Burn Pit Exposure, Chronic Migraine and Post-Traumatic Headache, Congenital Heart Disease, Constrictive Bronchiolitis, Diabetes, Dystonia, Eating Disorders, Emerging Viral Diseases, Endometriosis, Epidermolysis Bullosa, Familial Hypercholesterolemia, Fibrous Dysplasia, Focal Segmental Glomerulosclerosis, Food Allergies, Fragile X, Frontotemporal Degeneration, Guillain-Barr? Syndrome, Hemorrhage Control, Hepatitis B, Hydrocephalus, Immunomonitoring of Intestinal Transplants, Inflammatory Bowel Diseases, Interstitial Cystitis, Metals Toxicology, Mitochondrial Disease, Musculoskeletal Health, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Myotonic Dystrophy, Nutrition Optimization, Pancreatitis, Pathogen-Inactivated Blood Products, Plant-Based Vaccines, Polycystic Kidney Disease, Pressure Ulcers, Pulmonary Fibrosis, Resilience Training, Respiratory Health, Rheumatoid Arthritis, Sleep Disorders and Restriction, Spinal Muscular Atrophy, Sustained Release Drug Delivery, Vascular Malformation, Women?s Heart Disease Discovery Award Pre-application (letter of intent): April 16, 2020. Application: April 30, 2020. Focused Program Award Pre-application (preproposal): April 23, 2020. Application: August 6, 2020. Investigator-Initiated Research Award Pre-application (preproposal): April 23, 2020. Application: August 20, 2020. Technology/Therapeutic Development Award Pre-application (preproposal): April 23, 2020. Application: August 20, 2020. Med-RA deadline to receive draft documents for April 16, 2020 pre-applications: April 2. Med-RA deadline to receive draft documents for April 23, 2020 pre-applications: April 14. Simons Foundation Autism Research Initiative: Summer 2020 Pilot Award Grants awarded through this RFA are intended to provide early support for exploratory ideas, particularly those with novel hypotheses for autism. Appropriate projects for this mechanism include those considered higher risk with less assurance of ultimate impact, but with the potential for transformative results. Investigators new to the field of autism are encouraged to apply for these awards. The total budget of a Pilot Award is $300,000 or less, including 20 percent indirect costs, over a period of up to two (2) years. Due April 24, 2020. Med-RA deadline to receive draft documents: April 13. Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology, novel tools from data science approaches and m/eHealth, and implementation science research. Data generated through this research will be used to inform and evaluate context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S. Standard dates apply. Expires September 8, 2022. Med-RA deadline to receive draft documents for May 7, 2020 standard date: April 21. Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA), entitled ?Toward Translation of Cancer Nanotechnology Interventions (TTNCI)? is to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The ?Toward Translation of Nanotechnology Cancer Interventions? (TTNCI) awards are designed to mature experimental nanomedicines relying on ?next-generation? nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs. Due May 21, 2020; November 19, 2020; May 20, 2021; and November 18, 2021. Med-RA deadline to receive draft documents for May 21, 2020 deadline: May 11. Supporting Primary Care to Advance Cardiovascular Health in States with High Prevalence of Preventable CVD Events (U18) The Agency for Healthcare Research and Quality (AHRQ) seeks applications to disseminate and implement patient-centered outcomes research (PCOR) findings directly to primary care practices and support practices in implementing PCOR clinical and organizational findings. Applicants are expected to develop sustainable, State-based quality improvement support capacity through partnership with State and local organizations, build and engage a network of primary care practices, disseminate PCOR findings on heart health, and increase the capacity of primary care practices to implement evidence in the future. Due May 22, 2020. Med-RA deadline to receive draft documents: May 11. NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate. The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases. Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 12. NICHD Resource Program Grants in Bioinformatics (P41 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support the continued operation, enhancement, and dissemination of unique database bioinformatics resources that are of major importance to the research community using animal models of embryonic developmental processes. These grants will support ongoing development, maintenance, and enhancement of the resource, user training and services, provision of community-generated data storage and archiving, wide dissemination of the tools and/or resources, and establishment of interoperability with other NIH bioinformatics resources. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 12. Biomedical Technology Development and Dissemination Center (RM1 ? Clinical Trial Not Allowed) This funding opportunity announcement (FOA) encourages grant applications for national Biomedical Technology Development and Dissemination (BTDD) Centers. The BTDD program supports the development of technologies once their feasibility has been established and the dissemination of these technologies to the wider biomedical research community. The program encourages investigators to propose projects that address any of the biomedical research areas within the mission of NIGMS. The Centers are required to make their technologies available to the research community in a sustainable manner, to provide user training, and to disseminate the Center?s technologies and results. Centers should be at the leading edge of their field with respect to both technology development and engagement of the relevant research community. Potential applicants are strongly encouraged to contact NIGMS staff at least 10 weeks prior to the application due date to ascertain whether the proposed project is appropriate for an NIGMS BTDD Center. Due May 26, 2020; January 26, 2021; May 26, 2021; January 26, 2022; May 26, 2022; and January 26, 2023. Med-RA deadline to receive draft documents for May 26, 2020 deadline: May 12. Collaborative Program Grant for Multidisciplinary Teams (RM1 ? Clinical Trial Optional) This funding opportunity announcement (FOA) is designed to support highly integrated research teams of three to six PDs/PIs to address ambitious and challenging research questions that are important for the mission of NIGMS and are beyond the scope of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Project goals should not be achievable with a collection of individual efforts or projects. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields. Applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, creation of new technologies, or infrastructure development are not appropriate for this FOA. Due May 27, 2020; January 27, 2021; May 27, 2021; January 27, 2022; May 27, 2022; and January 27, 2023. Med-RA deadline to receive draft documents for May 27, 2020 deadline: May 13. NIH S10s: Shared Instrumentation Grant (SIG) Program, High-End Instrumentation (HEI) Grant Program, Shared Instrumentation for Animal Research (SIFAR) Grant Program SIG The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated systems. The minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $600,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers. HEI The High-End Instrumentation (HEI) Grant program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is $600,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, high throughput robotic screening systems, and biomedical imagers. SIFAR The Shared Instrumentation for Animal Research (SIFAR) Grant Program encourages applications from groups of NIH-funded investigators to purchase or upgrade scientific instruments necessary to carry out animal experiments in all areas of biomedical research supported by the NIH. Applicants may request clusters of commercially available instruments configured as specialized integrated systems or as series of instruments to support a thematic well-defined area of research using animals or related materials. Priority will be given to uniquely configured systems to support innovative and potentially transformative investigations. This FOA supports requests for state-of-the art commercially available technologies needed for NIH-funded research using any vertebrate and invertebrate animal species. This funding opportunity announcement (FOA) does not support requests for single instruments. At least one item of the requested instrumentation must cost at least $50,000, after all applicable discounts. No instrument in a cluster can cost less than $20,000, after all applicable discounts. There is no maximum price requirement; however, the maximum award is $750,000. Due June 1, 2020. Med-RA deadline to receive draft documents: May 18. Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of extracellular vesicles (EVs) and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of EVs as well as the computational analysis of the cargo carried in these vesicles. Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26. Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 / R01 Clinical Trials Not Allowed) R21 R01 These Funding Opportunity Announcements encourage research grant applications directed toward developing next-generation human cell-derived microphysiological systems and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26. Co-infection and Cancer (R21 / R01 Clinical Trial Not Allowed) R21 R01 The purpose of these Funding Opportunity Announcements is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents ? either concurrently or sequentially ? and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26. Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed) The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding. Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3. Improving Quality of Care and Patient Outcomes During Care Transitions (R01) The Agency for Healthcare Research and Quality?s (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to produce health services research that will rigorously test promising interventions aimed at improving communication and coordination during care transitions. Standard dates apply. Expires December 6, 2022. Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26. Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 ? Clinical Trial Optional) This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions. Standard dates apply. Expires November 17, 2022. Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3. Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional) This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064 or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions. Standard dates apply. Expires November 17, 2022. Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3. Molecular Mechanisms of Combination Adjuvants (MMCA) (U01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) solicits applications that propose studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are combined in these studies must already have shown individual immune modulating activity. Understanding the molecular and cellular mechanisms underlying the synergistic enhancement of immune responses by combination adjuvants will facilitate the rational selection of components for vaccines tailored to specific pathogens. The Cooperative Agreement grant mechanism allows for coordination of these research efforts with NIAID?s overall adjuvant research objectives. The long-term goal is to promote the development of novel adjuvant combinations that will improve the immunogenicity of vaccines while limiting or eliminating reactogenicity. Due June 29, 2020. Med-RA deadline to receive draft documents: June 16. Alzheimer?s Disease Sequencing Project Functional Genomics Consortium (U01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team-science strategy and apply high-throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimer?s disease and related dementias (AD/ADRD). Due July 1, 2020. Med-RA deadline to receive draft documents: June 18. Exploring the Mechanisms Underlying Modulation of Glymphatic-Lymphatic Systems by Complementary and Integrative Health Approaches (R21 / R01 Clinical Trial Optional) R21 R01 This Funding Opportunity Announcement (FOA) encourages research applications that explore the impact of and the mechanisms by which complementary and integrative health approaches regulate the activities of glymphatic/lymphatic systems, or investigate the effect of complementary and integrative health approaches on the interactions between glymphatic/lymphatic functions and physiological/pathological processes. Proposed mechanistic studies may be in relevant animal models and/or human research participants. This FOA will not support clinical trials aiming to assess efficacy or effectiveness of clinical outcomes. Due July 9, 2020. Med-RA deadline to receive draft documents: June 25. Exploring the Roles of Biomolecular Condensates (BMCs) in HIV replication, latency, or pathogenesis in the context of substance use disorders (R21 / R33 Clinical Trial Not Allowed) To support research projects exploring the roles of biomolecular condensates (BMCs) and their regulators in processes relevant to HIV/SIV infection, replication, latency, or pathogenesis in the context of substance use disorders. These processes could include studies exploring BMC involvement in HIV infection, HIV replication (including viral gene expression), HIV latency formation or maintenance (including chromatin structure), or HIV pathogenesis (including neurodegenerative processes). Studies could also include investigation of roles for BMCs or their regulators on host cell functions in the context of HIV infection, antiretroviral therapy, and/or exposure to addictive substances. Due July 20, 2020. Med-RA deadline to receive draft documents: July 7. Planning Projects for Clinical Trials on Effects of Sustained Reductions in Caloric Intake and Related Dietary Practices in Younger and Older Persons (U01 Clinical Trial Optional) This funding opportunity announcement (FOA) invites applications for 3-year planning projects for trials in either of two age ranges (25 to <50 or ?50 years of age) to determine the effects of sustained (e.g. 5-year) caloric restriction (CR) and other interventions that modify the amount, timing, or composition of nutrient intake on risk factors for aging-related conditions and mechanisms that may influence health span and longevity. Proposed projects must plan for trials with a minimum of three arms: a control group; a CR group; and at least one other nutritional intervention that modifies level, timing, or composition of nutrient intake. Narrower age ranges within the younger and older age groups may be proposed. The projects will support organizational, planning, and protocol development activities, addressing elements such as selection and design of interventions, recruitment, eligibility criteria, selection of pre-specified study outcomes, outcome ascertainment, behavioral interventions to achieve and maintain adherence, adherence measurement, and outcome analysis. The projects will also support pilot studies and data analyses needed for these planning activities. Due July 23, 2020. Med-RA deadline to receive draft documents: July 13. Research Education Program Grants for CryoEM and CryoET Curriculum Development (R25 Clinical Trial Not Allowed) The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this Common Fund R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation?s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Curriculum or Methods Development. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development in cryoelectron microscopy (cryoEM) and cryoelectron tomography (cryoET) for structural and cell biology research. Technical advances in cryoEM have resulted in its expanded use in generating reliable atomic models of complete and fully functional macromolecular complexes. An emerging related cryoEM method, cryoET, can image macromolecular assemblies in intact unstained frozen cells in three dimensions (3-D). Together, these methods enable high-resolution analysis of previously inaccessible levels of biological organization, ranging from below 100 kD to whole cells. Currently, demand for existing training opportunities exceeds capacity. Moreover, this demand is expected to rise as adoption of cryoEM and cryoET technology continues to increase. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on addressing instructional needs for new users of cryoEM and cryoET methods by supporting the development of online and computer-based instructional materials in these technologies. Due July 24, 2020. Med-RA deadline to receive draft documents: July 13. Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program. Due August 11, 2020; February 9, 2021; August 10, 2021; February 9, 2022; August 9, 2022; and February 9, 2023. Med-RA deadline to receive draft documents for August 11, 2020 deadline: July 29. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon Mar 16 15:20:20 2020 From: Research at med.fsu.edu (Med Research) Date: Mon, 16 Mar 2020 19:20:20 +0000 Subject: Weekly Funding Opportunities Message-ID: NIH and NSF Coronavirus Websites for the Research Community NIH: https://urldefense.com/v3/__https://grants.nih.gov/grants/natural_disasters/corona-virus.htm__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvwc8T8io$ NSF: https://urldefense.com/v3/__https://www.nsf.gov/news/special_reports/coronavirus/__;!!PhOWcWs!kVZbaNDjJ3Ry-NKIrtZTea5DIFBRvwXBgkriHSCtUNkj-ZWWFe-1JGE7yNRdTagd-QQxBIIOkaGvUx8-TbM$ Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) NIAID and NIGMS are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens. In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIAID is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest: * Studies to identify optimal 2019-nCoV in vitro culture requirements and conditions; * Development of reagents and assays for virus characterization; * Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission; * Studies to identify viral epitopes critical for binding neutralization; * Studies to examine virus stability and persistence; * Production of molecular clones of 2019-nCoV, reporter viruses and recombinant viral proteins; * Development of animal models of 2019-nCoV infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies; * Studies on the evolution and emergence of 2019-nCoV viruses including the identification of factors that affect viral host-range and virulence; * Virologic and serologic surveillance studies of the distribution and natural history of 2019-nCoV viruses in animal populations and in humans at the human/animal interface with particular emphasis on host reservoirs and understanding cross-species transmission events; * Development of sensitive, specific, and rapid clinical diagnostic tests for 2019-nCoV; * Development of 2019-nCoV therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of 2019-nCoV antiviral activity of existing or candidate therapeutics initially developed for other indications; * Identification and evaluation of the innate, cellular and humoral immune responses to 2019-nCoV infection and/or candidate vaccines, including, but not limited to: cross-reactive antibodies from individuals exposed to 2019-nCoV and other coronaviruses; viral epitopes critical for antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and * Development of 2019-nCoV vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates. NIGMS Interests * Incorporation of data related to the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of coronaviruses and related infectious agents. Expires February 6, 2021. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor. Division of Integrative Organismal Systems Core Programs and Rules of Life The Division of Integrative Organismal Systems (IOS) Core Programs Track supports research aimed at understanding why organisms are structured the way they are and function as they do. Proposals are welcomed in all of the core scientific program areas supported by the Division of Integrative Organismal Systems (IOS). Areas of inquiry include, but are not limited to, developmental biology and the evolution of developmental processes, nervous system development, structure, modification, function, and evolution; biomechanics and functional morphology, physiological processes, symbioses and microbial interactions, interactions of organisms with biotic and abiotic environments, plant and animal genomics, and animal behavior. Proposals should focus on organisms as a fundamental unit of biological organization. Principal Investigators (PIs) are encouraged to apply systems approaches that will lead to conceptual and theoretical insights and predictions about emergent organismal properties. The four clusters in IOS which are participating in submissions to this solicitation are: Behavioral Systems Cluster: The Behavioral Systems cluster contains the Animal Behavior Program. Developmental Systems Cluster: Programs within the Developmental Systems Cluster are: the Plant, Fungal and Microbial Developmental Mechanisms Program, the Animal Developmental Mechanisms Program and the Evolution of Developmental Mechanisms Program. Neural Systems Cluster: Programs within the Neural Systems Cluster are the Organization Program, the Activation Program and the Modulation Program. Physiological and Structural Systems Cluster: Programs within the Physiological and Structural Systems Cluster are: the Symbiosis, Defense and Self-recognition Program (SDS), the Physiological Mechanisms and Biomechanics Program (PMB), the Integrative Ecological Physiology Program (IEP) and the NSF-NIFA Plant Biotic Interactions Program (PBI). The Rules of Life Track supports integrative proposals that span the subcellular and cellular scales normally funded by MCB to the organ, tissue, organismal, and group scale typically funded by IOS, to population, species, community and ecosystem scales typically funded by DEB. Rules of Life proposals may also include enabling infrastructure through joint submission with DBI. Discovery of fundamental principles and enabling infrastructure will advance understanding and further predict how key properties of living systems emerge from the interaction of genomes, phenotypes, and developmental, social and environmental context across space and time. This track provides opportunities to advance understanding of the Rules of Life by new mechanisms for review and funding of proposals that span two or more divisions in the Biological Sciences Directorate. Applications welcome anytime. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor. Foundation for Women?s Wellness Research Awards FWW Research Awards target small, short-term studies with promise for improving medical care in leading women?s health concerns including cardiovascular disease, female cancers, the role of hormones in disease and stage-of-life health issues like pregnancy and menopause and diseases disproportionately affecting women. WW Research Awards are one-time, non-recurring $25,000. Due April 6, 2020. Med-RA deadline to receive draft documents: March 24. WITH Foundation: Healthcare for Adults with Developmental Disabilities The WITH Foundation is inviting letters of intent from organizations for efforts to promote comprehensive health care for adults with developmental disabilities. Grants will be awarded in support of programs that improve delivery of health care to adult consumers with developmental disabilities that include at least one of the following facets: improve health practitioner competency through education and/or training programs; address the current inadequate reimbursement system; advance formal care coordination; enhance public awareness regarding the inadequacies of developmentally disabled care in order to advance systemic change; increase understanding of supported decision-making in healthcare settings; national efforts in digital health that support designers and developers to include the perspectives/experiences of the IDD community within the design process in order to create better technology for all; social policy research; and identify and overcome barriers to high-quality healthcare access. The foundation typically provides a year of support, of usually between $30,000 and $50,000, but may cover as much as three years to support programming that warrants extended funding. Letter of intent due April 16, 2020. Med-RA deadline to receive draft documents: April 6. Congressionally Directed Medical Research Programs Bone Marrow Failure Research Program Idea Development Award Pre-application (preproposal): May 11, 2020. Application: August 5, 2020. Med-RA deadline to receive draft documents for May 11, 2020 preproposal deadline: April 28. Lung Cancer Research Program Concept Award Pre-application (required letter of intent): May 27, 2020. Invited full application: June 10, 2020. Med-RA deadline to receive draft documents for May 27 letter of intent deadline: May 13. Idea Development Award Pre-application (preproposal): May 6, 2020. Invited full application: July 29, 2020. Investigator-Initiated Translational Research Award Pre-application (preproposal): May 6, 2020. Invited full application: July 29, 2020. Med-RA deadline to receive draft documents for May 6, 2020 preproposal deadline: April 23. Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs (NIA or NIAID). Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years. Due May 13, 2020; September 13, 2020; January 13, 2021; May 13, 2021; September 13, 2021; January 13, 2022; May 13, 2022; September 13, 2022; and January 13, 2023. Med-RA deadline to receive draft documents for May 13, 2020 preproposal deadline: April 30. In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. As of November 2019, the IMPC-KOMP2 KO mouse phenotyping effort has generated mutants in 9,051 mouse genes, completed phenotypes of 7153 lines, and released data for 6255 lines corresponding to 5861 mutant genes. Overall, the IMPC hopes to achieve broad-based phenotyping of roughly 20,000 KO strains. About 30% of these strains either are expected to be embryonic or perinatal lethal, or subviable. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research. Due June 5, 2020; October 5, 2020; June 5, 2021; October 5, 2021; June 5, 2022; and October 5, 2022. Med-RA deadline to receive draft documents for June 5, 2020 deadline: May 26. Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26. Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant. Due June 29, 2020. Med-RA deadline to receive draft documents: June 16. Engineering Immunity to HIV-1 Through Next Generation Vaccines (R61 / R33 Clinical Trial Not Allowed) The objective of this Funding Opportunity Announcement (FOA) is to pair Bioengineers and Immunologists to leverage emerging innovative knowledge in physical and computational sciences for the design and development of an HIV-1 vaccine. Due July 28, 2020. Med-RA deadline to receive draft documents: July 15. Alzheimer?s Disease Research Centers (P30 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers (ADRCs). NIA-designated ADRCs serve as major sources of discovery into the nature of Alzheimer?s disease and Alzheimer's disease-related dementias (AD/ADRD) and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators. Due September 15, 2020. Med-RA deadline to receive draft documents: September 1. Network for Identification, Evaluation, and Tracking of Older Persons with Superior Cognitive Performance for Their Chronological Age (U19 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) invites applications to establish a network to identify, evaluate, track, and conduct research across multiple sites on older adults with superior cognitive performance for their age ("cognitive super agers"). The activity would support aggregation of sufficient numbers of these individuals to advance the field?s understanding of factors that promote sustained cognitive health and those that are not of primary importance. Uniform identification and uniform data collection will allow the study of the behavioral, neurological, health, genetic, environmental, and lifestyle profiles that lead to sustained cognitive and brain function in advanced age. Where extant data exists, harmonization protocols would need to be developed in order to make use of all currently available data. Provision of protocols to obtain brain tissue at autopsy would be an important component. Due October 1, 2020. Med-RA deadline to receive draft documents: September 21. Maximizing Investigators? Research Award (MIRA) for Early Stage Investigators (R35 ? Clinical Trial Optional) The Maximizing Investigators' Research Award (MIRA) under this FOA is a grant to provide support for a program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program of research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this FOA will: * Enable investigators to apply earlier in their independent research careers, allowing them to secure grant funding that will launch and sustain successful research careers. * Enhance investigators' ability to move into research areas that are distinct from those of their postdoctoral mentors, which could lead to new scientific discoveries. * Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively. * Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies. * More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs. * Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research. * Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment. Due October 2, 2020; October 4, 2021; and October 3, 2022. Med-RA deadline to receive draft documents for October 2, 2020 deadline: September 21. Central and Peripheral Control of Balance in Older Adults (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites applications that propose basic and/or clinical studies to investigate central and peripheral control of balance in older adults and/or in relevant animal models. This FOA is driven by the need to address a major gap in our understanding of how aging impacts the vestibular system, which, when impaired, contributes to balance problems and an increased risk of falls in older adults. Additionally, given that balance impairment can be attributed to a number of factors (e.g. sensory, motor, cognitive, psychological, and vascular function), understanding the contribution of age-related vestibular loss, and how this interacts with these factors, is critical for informing interventions and treatments for balance problems and falls in older adults. Due October 2, 2020. Med-RA deadline to receive draft documents: September 21. Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required The purpose of this funding opportunity announcement (FOA) is to fund well-controlled studies in support of a new indication or change in labeling of products to address unmet needs in rare diseases or conditions. Through the funding of efficient and innovative clinical studies evaluating safety and/or efficacy, FDA expects to increase the number of treatments for rare diseases with an unmet medical need and exert a broad and positive impact on rare disease drug development. Due October 6, 2020 and October 5, 2021. Med-RA deadline to receive draft documents for October 6, 2020 deadline: September 23. New/Unconventional Animal Models of Alzheimer?s Disease (R24 Clinical Trial Not Allowed) This funding opportunity announcement (FOA) invites research to develop, characterize, and validate new, unconventional, or innovative non-rodent mammalian models of late-onset (sporadic) Alzheimer's Disease (AD). These new models are expected to recapitulate molecular, cellular, neuropathological, behavioral, and/or cognitive hallmarks and aspects of late-onset AD. Research supported under this FOA is expected to provide new investigative tools to identify the gaps in current knowledge related to molecular mechanisms of late-onset AD and identify potential therapeutic targets. Due October 7, 2020. Med-RA deadline to receive draft documents: September 24. Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R34 / R01 Clinical Trial Optional) R34 The purpose of this Funding Opportunity Announcement (FOA) is to encourage practice-based research aimed at refining and pilot testing developmentally-focused, theory-based efficacious prevention interventions that may impact mental health outcomes, including suicide behaviors and serious mental illness. The research should test prevention approaches that are both scalable and sustainable for implementation in pediatric-serving primary care settings, with an emphasis on populations experiencing mental health disparities. R01 The purpose of this FOA is to encourage practice-based research aimed at testing the effectiveness of developmentally-focused theory-based efficacious prevention interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. The research should test prevention approaches that are both scalable and sustainable for implementation in pediatric-serving primary care settings, with an emphasis on populations experiencing mental health disparities. This FOA seeks to support clinical trials to establish the effectiveness of scalable prevention interventions when implemented using available resources within pediatric-serving primary care settings. Due October 15, 2020. Med-RA deadline to receive draft documents: October 5. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon Mar 16 17:03:36 2020 From: Research at med.fsu.edu (Med Research) Date: Mon, 16 Mar 2020 21:03:36 +0000 Subject: Weekly Funding Opportunities Message-ID: NIH and NSF Coronavirus Websites for the Research Community NIH: https://urldefense.com/v3/__https://grants.nih.gov/grants/natural_disasters/corona-virus.htm__;!!PhOWcWs!nMeo0TZnnVSAB5HAT_bmr4wB8V6x9OvFYd8z9_3v4JDxZyXv1af7RRcDDdh4xIQt75PePL98v7D-bv2xHQk$ NSF: https://urldefense.com/v3/__https://www.nsf.gov/news/special_reports/coronavirus/__;!!PhOWcWs!nMeo0TZnnVSAB5HAT_bmr4wB8V6x9OvFYd8z9_3v4JDxZyXv1af7RRcDDdh4xIQt75PePL98v7D-ld3XqYw$ Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) NIAID and NIGMS are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens. In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIAID is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest: * Studies to identify optimal 2019-nCoV in vitro culture requirements and conditions; * Development of reagents and assays for virus characterization; * Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission; * Studies to identify viral epitopes critical for binding neutralization; * Studies to examine virus stability and persistence; * Production of molecular clones of 2019-nCoV, reporter viruses and recombinant viral proteins; * Development of animal models of 2019-nCoV infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies; * Studies on the evolution and emergence of 2019-nCoV viruses including the identification of factors that affect viral host-range and virulence; * Virologic and serologic surveillance studies of the distribution and natural history of 2019-nCoV viruses in animal populations and in humans at the human/animal interface with particular emphasis on host reservoirs and understanding cross-species transmission events; * Development of sensitive, specific, and rapid clinical diagnostic tests for 2019-nCoV; * Development of 2019-nCoV therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of 2019-nCoV antiviral activity of existing or candidate therapeutics initially developed for other indications; * Identification and evaluation of the innate, cellular and humoral immune responses to 2019-nCoV infection and/or candidate vaccines, including, but not limited to: cross-reactive antibodies from individuals exposed to 2019-nCoV and other coronaviruses; viral epitopes critical for antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and * Development of 2019-nCoV vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates. NIGMS Interests * Incorporation of data related to the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of coronaviruses and related infectious agents. Expires February 6, 2021. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor. Division of Integrative Organismal Systems Core Programs and Rules of Life The Division of Integrative Organismal Systems (IOS) Core Programs Track supports research aimed at understanding why organisms are structured the way they are and function as they do. Proposals are welcomed in all of the core scientific program areas supported by the Division of Integrative Organismal Systems (IOS). Areas of inquiry include, but are not limited to, developmental biology and the evolution of developmental processes, nervous system development, structure, modification, function, and evolution; biomechanics and functional morphology, physiological processes, symbioses and microbial interactions, interactions of organisms with biotic and abiotic environments, plant and animal genomics, and animal behavior. Proposals should focus on organisms as a fundamental unit of biological organization. Principal Investigators (PIs) are encouraged to apply systems approaches that will lead to conceptual and theoretical insights and predictions about emergent organismal properties. The four clusters in IOS which are participating in submissions to this solicitation are: Behavioral Systems Cluster: The Behavioral Systems cluster contains the Animal Behavior Program. Developmental Systems Cluster: Programs within the Developmental Systems Cluster are: the Plant, Fungal and Microbial Developmental Mechanisms Program, the Animal Developmental Mechanisms Program and the Evolution of Developmental Mechanisms Program. Neural Systems Cluster: Programs within the Neural Systems Cluster are the Organization Program, the Activation Program and the Modulation Program. Physiological and Structural Systems Cluster: Programs within the Physiological and Structural Systems Cluster are: the Symbiosis, Defense and Self-recognition Program (SDS), the Physiological Mechanisms and Biomechanics Program (PMB), the Integrative Ecological Physiology Program (IEP) and the NSF-NIFA Plant Biotic Interactions Program (PBI). The Rules of Life Track supports integrative proposals that span the subcellular and cellular scales normally funded by MCB to the organ, tissue, organismal, and group scale typically funded by IOS, to population, species, community and ecosystem scales typically funded by DEB. Rules of Life proposals may also include enabling infrastructure through joint submission with DBI. Discovery of fundamental principles and enabling infrastructure will advance understanding and further predict how key properties of living systems emerge from the interaction of genomes, phenotypes, and developmental, social and environmental context across space and time. This track provides opportunities to advance understanding of the Rules of Life by new mechanisms for review and funding of proposals that span two or more divisions in the Biological Sciences Directorate. Applications welcome anytime. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor. Foundation for Women's Wellness Research Awards FWW Research Awards target small, short-term studies with promise for improving medical care in leading women's health concerns including cardiovascular disease, female cancers, the role of hormones in disease and stage-of-life health issues like pregnancy and menopause and diseases disproportionately affecting women. WW Research Awards are one-time, non-recurring $25,000. Due April 6, 2020. Med-RA deadline to receive draft documents: March 24. WITH Foundation: Healthcare for Adults with Developmental Disabilities The WITH Foundation is inviting letters of intent from organizations for efforts to promote comprehensive health care for adults with developmental disabilities. Grants will be awarded in support of programs that improve delivery of health care to adult consumers with developmental disabilities that include at least one of the following facets: improve health practitioner competency through education and/or training programs; address the current inadequate reimbursement system; advance formal care coordination; enhance public awareness regarding the inadequacies of developmentally disabled care in order to advance systemic change; increase understanding of supported decision-making in healthcare settings; national efforts in digital health that support designers and developers to include the perspectives/experiences of the IDD community within the design process in order to create better technology for all; social policy research; and identify and overcome barriers to high-quality healthcare access. The foundation typically provides a year of support, of usually between $30,000 and $50,000, but may cover as much as three years to support programming that warrants extended funding. Letter of intent due April 16, 2020. Med-RA deadline to receive draft documents: April 6. Congressionally Directed Medical Research Programs Bone Marrow Failure Research Program Idea Development Award Pre-application (preproposal): May 11, 2020. Application: August 5, 2020. Med-RA deadline to receive draft documents for May 11, 2020 preproposal deadline: April 28. Lung Cancer Research Program Concept Award Pre-application (required letter of intent): May 27, 2020. Invited full application: June 10, 2020. Med-RA deadline to receive draft documents for May 27 letter of intent deadline: May 13. Idea Development Award Pre-application (preproposal): May 6, 2020. Invited full application: July 29, 2020. Investigator-Initiated Translational Research Award Pre-application (preproposal): May 6, 2020. Invited full application: July 29, 2020. Med-RA deadline to receive draft documents for May 6, 2020 preproposal deadline: April 23. Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs (NIA or NIAID). Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years. Due May 13, 2020; September 13, 2020; January 13, 2021; May 13, 2021; September 13, 2021; January 13, 2022; May 13, 2022; September 13, 2022; and January 13, 2023. Med-RA deadline to receive draft documents for May 13, 2020 preproposal deadline: April 30. In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. As of November 2019, the IMPC-KOMP2 KO mouse phenotyping effort has generated mutants in 9,051 mouse genes, completed phenotypes of 7153 lines, and released data for 6255 lines corresponding to 5861 mutant genes. Overall, the IMPC hopes to achieve broad-based phenotyping of roughly 20,000 KO strains. About 30% of these strains either are expected to be embryonic or perinatal lethal, or subviable. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research. Due June 5, 2020; October 5, 2020; June 5, 2021; October 5, 2021; June 5, 2022; and October 5, 2022. Med-RA deadline to receive draft documents for June 5, 2020 deadline: May 26. Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26. Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant. Due June 29, 2020. Med-RA deadline to receive draft documents: June 16. Engineering Immunity to HIV-1 Through Next Generation Vaccines (R61 / R33 Clinical Trial Not Allowed) The objective of this Funding Opportunity Announcement (FOA) is to pair Bioengineers and Immunologists to leverage emerging innovative knowledge in physical and computational sciences for the design and development of an HIV-1 vaccine. Due July 28, 2020. Med-RA deadline to receive draft documents: July 15. Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers (ADRCs). NIA-designated ADRCs serve as major sources of discovery into the nature of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators. Due September 15, 2020. Med-RA deadline to receive draft documents: September 1. Network for Identification, Evaluation, and Tracking of Older Persons with Superior Cognitive Performance for Their Chronological Age (U19 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) invites applications to establish a network to identify, evaluate, track, and conduct research across multiple sites on older adults with superior cognitive performance for their age ("cognitive super agers"). The activity would support aggregation of sufficient numbers of these individuals to advance the field's understanding of factors that promote sustained cognitive health and those that are not of primary importance. Uniform identification and uniform data collection will allow the study of the behavioral, neurological, health, genetic, environmental, and lifestyle profiles that lead to sustained cognitive and brain function in advanced age. Where extant data exists, harmonization protocols would need to be developed in order to make use of all currently available data. Provision of protocols to obtain brain tissue at autopsy would be an important component. Due October 1, 2020. Med-RA deadline to receive draft documents: September 21. Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional) The Maximizing Investigators' Research Award (MIRA) under this FOA is a grant to provide support for a program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program of research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this FOA will: * Enable investigators to apply earlier in their independent research careers, allowing them to secure grant funding that will launch and sustain successful research careers. * Enhance investigators' ability to move into research areas that are distinct from those of their postdoctoral mentors, which could lead to new scientific discoveries. * Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively. * Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies. * More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs. * Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research. * Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment. Due October 2, 2020; October 4, 2021; and October 3, 2022. Med-RA deadline to receive draft documents for October 2, 2020 deadline: September 21. Central and Peripheral Control of Balance in Older Adults (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites applications that propose basic and/or clinical studies to investigate central and peripheral control of balance in older adults and/or in relevant animal models. This FOA is driven by the need to address a major gap in our understanding of how aging impacts the vestibular system, which, when impaired, contributes to balance problems and an increased risk of falls in older adults. Additionally, given that balance impairment can be attributed to a number of factors (e.g. sensory, motor, cognitive, psychological, and vascular function), understanding the contribution of age-related vestibular loss, and how this interacts with these factors, is critical for informing interventions and treatments for balance problems and falls in older adults. Due October 2, 2020. Med-RA deadline to receive draft documents: September 21. Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required The purpose of this funding opportunity announcement (FOA) is to fund well-controlled studies in support of a new indication or change in labeling of products to address unmet needs in rare diseases or conditions. Through the funding of efficient and innovative clinical studies evaluating safety and/or efficacy, FDA expects to increase the number of treatments for rare diseases with an unmet medical need and exert a broad and positive impact on rare disease drug development. Due October 6, 2020 and October 5, 2021. Med-RA deadline to receive draft documents for October 6, 2020 deadline: September 23. New/Unconventional Animal Models of Alzheimer's Disease (R24 Clinical Trial Not Allowed) This funding opportunity announcement (FOA) invites research to develop, characterize, and validate new, unconventional, or innovative non-rodent mammalian models of late-onset (sporadic) Alzheimer's Disease (AD). These new models are expected to recapitulate molecular, cellular, neuropathological, behavioral, and/or cognitive hallmarks and aspects of late-onset AD. Research supported under this FOA is expected to provide new investigative tools to identify the gaps in current knowledge related to molecular mechanisms of late-onset AD and identify potential therapeutic targets. Due October 7, 2020. Med-RA deadline to receive draft documents: September 24. Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R34 / R01 Clinical Trial Optional) R34 The purpose of this Funding Opportunity Announcement (FOA) is to encourage practice-based research aimed at refining and pilot testing developmentally-focused, theory-based efficacious prevention interventions that may impact mental health outcomes, including suicide behaviors and serious mental illness. The research should test prevention approaches that are both scalable and sustainable for implementation in pediatric-serving primary care settings, with an emphasis on populations experiencing mental health disparities. R01 The purpose of this FOA is to encourage practice-based research aimed at testing the effectiveness of developmentally-focused theory-based efficacious prevention interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. The research should test prevention approaches that are both scalable and sustainable for implementation in pediatric-serving primary care settings, with an emphasis on populations experiencing mental health disparities. This FOA seeks to support clinical trials to establish the effectiveness of scalable prevention interventions when implemented using available resources within pediatric-serving primary care settings. Due October 15, 2020. Med-RA deadline to receive draft documents: October 5. To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog. Please Note: Florida has very broad public records laws. Most written communications to or from state/university employees and students are public records and available to the public and media upon request. Your e-mail communications may, therefore, be subject to public disclosure. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon Mar 23 14:39:38 2020 From: Research at med.fsu.edu (Med Research) Date: Mon, 23 Mar 2020 18:39:38 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE01E6DDEFAE@FSUCOM128.med.ad.fsu.edu> Patient-oriented Research to Mitigate Health Disparities and Lessen the Burden of Chronic Diseases Within the Mission of NIDDK (R01 Clinical Trial Optional) This Funding Opportunity Announcement invites applications to conduct patient-oriented clinical research studies designed to develop strategies to mitigate health disparities in people with one or more chronic diseases or conditions within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Populations of interest include those disproportionately burdened with multiple chronic conditions and/or disparities in social, behavioral and/or biological risk factors. Only studies that involve interaction with human participants will be considered appropriate for this FOA. Due May 22, 2020. Med-RA deadline to receive draft documents: May 11. Amgen Foundation: Migraine Research Amgen's Competitive Grant Program in Migraine Research will provide an opportunity for early career investigators in the United States to compete for individual grants of US$50,000?150,000 for novel research proposals that seek to advance the medical knowledge of migraine. The program is limited to proposals from early career investigators (interns, residents, headache medicine fellows, and healthcare professionals within 5 years of completion of training) based in the United States and requires a letter of recommendation from their department or laboratory head. Specific predefined areas of research eligible for a Competitive Grant Program in Migraine Research award include: * Non-interventional clinical research with a focus on early diagnosis and treatment, epidemiology, and Patient Reported Outcomes (PRO)/Quality of Life (QoL) measures. * Biomarkers for diagnosis and prognosis. * Preclinical research focused on mechanism of disease (non-calcitonin gene-related peptide [CGRP]- and non-pituitary adenylate cyclase-activating polypeptide [PACAP]-related). Due May 22, 2020. Med-RA deadline to receive draft documents: May 11. Center of Excellence for Research on Complementary and Integrative Health (P01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) encourages the submission of applications requiring multi-project, synergistic collaborations blending multiple research approaches from outstanding multidisciplinary research teams. This Center of Excellence for Research on Complementary and Integrative Health (CERCIH) program is designed to support three or more highly meritorious projects that can offer significant scientific advantages and ?synergy? that could not be achieved by supporting the same projects as individual research grants. Each CERCIH must be focused on questions of high relevance to the mission of NCCIH and high research priority based on the current Strategic Plan. Applications in response to this FOA may propose to involve human participants in mechanistic studies, but this FOA will not support clinical trials of efficacy or effectiveness. Standard dates apply. Expires May 26, 2023. Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 12. Congressionally Directed Medical Research Programs Military Burn Research Program Clinical Translational Research Award Pre-application (prepropsal): May 15, 2020. Invited full application: August 20, 2020. Med-RA deadline to receive draft documents for pre-application: May 4. Peer Reviewed Orthopaedic Research Program Applied Research Award Pre-application (preproposal): May 27, 2020. Application: September 10, 2020. Clinical Trial Award Pre-application (preproposal): May 27, 2020. Application: September 10, 2020. Med-RA deadline to receive draft documents for pre-application: May 18. Clinical Translational Research Award Pre-application: April 15, 2020. Invited full application: July 16, 2020. Med-RA deadline to receive draft documents for pre-application: April 2. Prostate Cancer Research Program Early Investigator Research Award Pre-application (letter of intent): June 4, 2020. Confidential letters of recommendation: June 23, 2020. Application: June 18, 2020. Physician Research Award Pre-application (letter of intent): June 4, 2020. Confidential letters of recommendation: June 23, 2020. Application: June 18, 2020. Med-RA deadline to receive draft documents for pre-application: May 26. Spinal Cord Injury Research Program Clinical Trial Award Pre-application (preproposal): May 21, 2020. Application: August 25, 2020. Translational Research Award Pre-application (preproposal): May 21, 2020. Application: August 25, 2020. Investigator Initiated Research Award Pre-application (preproposal): May 21, 2020. Application: August 25, 2020. Med-RA deadline to receive draft documents for pre-application: May 11. Tick-Borne Disease Research Program Career Development Award Pre-application (preproposal): May 27, 2020. Invited full application: August 27, 2020. Idea Award Pre-application (preproposal): May 27, 2020. Invited full application: August 27, 2020. Med-RA deadline to receive draft documents for pre-application: May 18. Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional) This Funding Opportunity Announcement invites applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g., screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan. In this program announcement, screening is defined as a preventive service focused on detection of an undiagnosed disease in asymptomatic populations. Research supported by this initiative should enhance the screening process related to use: (1) in diverse populations, (2) in diverse clinical and community settings, and/or (3) with traditional, non-traditional and/or allied health care providers. Standard dates apply. Due January 8, 2022. Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26. Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3. Novel Synthetic Nucleic Acid Technology Development (R21 / R01) (Clinical Trial not allowed) R21 R01 These Funding Opportunity Announcements (FOA) solicit grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities, and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. Due June 24, 2020; February 1, 2021; October 1, 2021; and June 24, 2022. Med-RA deadline to receive draft documents for June 24, 2020 deadline: June 11. Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional) Note: For this U01, ?limited competition? means (1) only institutions with a CTSA can apply, and (2) the application must include investigators from three (or more) program hub institutions. The UF-FSU CTSA is a single hub. The Clinical and Translational Science Award (CTSA) Program Collaborative Innovation Award (CCIA) supports collaborative research activities that develop innovative solutions that will improve the efficiency, quality and impact of turning laboratory, clinic and community observations into interventions that improve the health of individuals and the public. This funding opportunity announcement (FOA) will support investigators from three or more CTSA Program hub institutions (see current UL1 awardees) to either: 1) form new collaborations, or to 2) significantly expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre-existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed at one hub to other hubs, in so doing testing its robustness to different hub environments and structures and adapting it for further dissemination within outside the CTSA Program consortium if appropriate. Due July 10, 2020; November 9, 2020; March 8, 2021; July 9, 2021; and November 9, 2021. Med-RA deadline to receive draft documents for July 10, 2020 deadline: June 29. Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional) Note: For this U01, ?limited competition? means (1) only institutions with a CTSA can apply, and (2) the application must include investigators from two (or more) program hub institutions. The UF-FSU CTSA is a single hub. The Clinical and Translational Science Award (CTSA) Program Collaborative Innovation Award (CCIA) supports collaborative research activities that develop innovative solutions that will improve the efficiency, quality and impact of turning laboratory, clinic and community observations into interventions that improve the health of individuals and the public. This funding opportunity announcement (FOA) will support investigators from two or more CTSA Program hub institutions (see current UL1 awardees) to either: 1) form new collaborations, or to 2) significantly expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre- existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed at one hub to other hubs, in so doing testing its robustness to different hub environments and structures and adapting it for further dissemination within outside the CTSA Program consortium if appropriate. Due July 10, 2020; November 9, 2020; March 8, 2021; July 9, 2021; and November 9, 2021. Med-RA deadline to receive draft documents for July 10, 2020 deadline: June 29. Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R21 / R01 Clinical Trial Optional) R21 R01 Through these Funding Opportunity Announcements (FOAs), the National Cancer Institute invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent, and young adult (AYA) cancer survivors. Specifically, these FOAs solicit mechanistic, observational, and intervention applications that focus on six key domains: (1) disparities in survivor outcomes; (2) barriers to follow-up care (e.g., access, adherence); (3) impact of familial, socioeconomic, and other environmental factors on survivor outcomes; (4) indicators for long-term follow-up needs related to risk for late effects, recurrence, and subsequent cancers; (5) risk factors and predictors of late/long-term effects of cancer treatment; and (6) development of targeted interventions to reduce the burden of cancer for pediatric/AYA survivors. Due July 31, 2020 and July 30, 2021. Med-RA deadline to receive draft documents for July 31, 2020 deadline: July 20. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Thu Mar 26 08:26:15 2020 From: Research at med.fsu.edu (Med Research) Date: Thu, 26 Mar 2020 12:26:15 +0000 Subject: FW: Deadline extension: Two Harrington grant funding opportunities In-Reply-To: <4D9C9F30E713E749A1848A11139F46AA62AAE6D6@FSUCOM127.med.ad.fsu.edu> References: <05081C4FED687846AFCCEDCDFFFE726BA1272DE4@UHE10MB07.uhhs.com> <4D9C9F30E713E749A1848A11139F46AA62AAE6D6@FSUCOM127.med.ad.fsu.edu> Message-ID: <60E19361B71BE04F835C1FB3C18361BE01E6DDF0B3@FSUCOM128.med.ad.fsu.edu> REMINDER: Please notify Med-RA if you plan to apply (or collaborate with another applicant) for either of these opportunities. Email us at: research at med.fsu.edu. 2021 HARRINGTON SCHOLAR-INNOVATOR AWARD ? DEADLINE EXTENDED! M.D. required. Open to physician-scientists in the U.S. and Canada. Letters of Intent (LOI) due: April 10, 2020. Full applications due May 22 for those invited to submit. * All disease areas. * $100,000 guaranteed; opportunity to qualify for up to $700,000. * Dedicated drug discovery and development support. For more information, visit HarringtonDiscovery.org/grant. To submit an LOI, go to HDI?s grant system and create an account. **If you would like to submit an LOI and it is difficult for you to access the online system prior to the deadline, email Rebecca.Haag at HarringtonDiscovery.org and she will send you the LOI fields in a Word document. 2020 ADDF-HARRINGTON SCHOLAR AWARD ? DEADLINE EXTENDED! A partner program with the Alzheimer?s Drug Discovery Foundation (ADDF). Ph.D. or M.D. or equivalent required. Open to researchers in the U.S., U.K. and Canada. Letters of Intent (LOI) due: May 18, 2020. Full applications due August 10 for those invited to submit. * Alzheimer?s disease and related dementias. Of particular interest are targets related to proteostasis and neurovascular health. * Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer?s field are encouraged to apply. * Financial support of up to $600,000 over two years. * Dedicated drug discovery and development support. For more information, visit HarringtonDiscovery.org/ADDF. To submit an online application, go to ADDF?s funding system and create an account. Scientific questions about your proposal? Contact Meriel Owen, PhD, Alzheimer?s Drug Discovery Foundation at mowen at alzdiscovery.org. If you are interested to apply for these opportunities, please reach out to Bronwyn Monroe for assistance with your LOI. Bronwyn Monroe Program Director Harrington Discovery Institute phone: 216-675-6803 email: Bronwyn.Monroe at HarringtonDiscovery.org web: HarringtonDiscovery.org -------------- next part -------------- An HTML attachment was scrubbed... URL: